Successfully targeting triple negative breast cancer using combination therapy of didox and doxorubicin with reduced cardiotoxicity
Introduction/Abstract
Triple-negative breast cancer (TNBC) is an aggressive histological subtype that has limited treatment options with chemotherapy being the only systemic therapy for these patients. The most common chemotherapy regimen used includes the anthracycline Doxorubicin (DOXO). Although DOXO is a highly effective agent, its efficacy is limited due to acquired drug resistance and cardiotoxicity.
Location
DUC Ballroom A&B
Format
Poster Presentation
Successfully targeting triple negative breast cancer using combination therapy of didox and doxorubicin with reduced cardiotoxicity
DUC Ballroom A&B
Triple-negative breast cancer (TNBC) is an aggressive histological subtype that has limited treatment options with chemotherapy being the only systemic therapy for these patients. The most common chemotherapy regimen used includes the anthracycline Doxorubicin (DOXO). Although DOXO is a highly effective agent, its efficacy is limited due to acquired drug resistance and cardiotoxicity.
